Background
• Wolfram syndrome is a rare genetic disorder with an estimated prevalence of 1 in 770,000 people in the UK. 1 It is therefore expected that approximately 80 patients are currently living with the condition.
• Wolfram syndrome, also known as DIDMOAD, is a progressive and neurodegenerative disease characterised by four key symptoms: diabetes insipidus (DI), diabetes mellitus (DM), optic atrophy (OA) and deafness (D) (Figure 1 ).
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• In addition, patients can manifest a range of other symptoms, including psychiatric problems and neurological abnormalities.
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Conclusions
• The annual cost of Wolfram syndrome to the NHS per patient was found to be considerable.
• The results of this study highlight a number of areas of potential cost-savings where the development of an effective treatment to halt progression and provide better control of symptoms is needed.
Methods
• A COI model was built reflecting the standard practice of the UK Wolfram syndrome specialist service.
• A prevalence-based approach was used and only direct costs to the NHS were considered.
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• Information provided by patients with Wolfram syndrome and their families at a focus group in April 2016 was also included.
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• All inputs were verified by a clinical expert.
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• Key model inputs are presented in Table 1 .
• Costs were calculated across symptom groups and auxiliary running costs for the paediatric specialist clinics were included.
• A deterministic sensitivity analysis (DSA) was run at 10% to identify the major cost drivers of the model.
Results
The total COI to the NHS was £990,588.45 per year
• The final COI of all people with Wolfram syndrome to the NHS and the average cost per patient is shown in Figure 2 .
Costs associated with diabetes mellitus had the greatest contribution to total costs
• The costs associated with diabetes mellitus care, late-stage complications of diabetes mellitus, hearing impairment, and visual impairment made the greatest contribution to the final COI (Figure 3) .
The greatest driver of the COI was the proportion of patients with sensorineural hearing impairment
• The DSA identified costs associated with hearing impairment and diabetes mellitus as major drivers in the model (Figure 4 ). 
